The subset of patients in these two trials who received the doses comparable to the Phase 3 dose showed median survival of 34.9 months and 35.0 months, respectively.
I would assume that they picked the max dose to carry forward into the ph iii? Did they release a p value for efficacy vs dose trend in pre-defined dose subgroups?
Did they release the size of that subpopulation with the 34.9 and 35.0 months median survival (one of them was ~22 patients, the other much smaller?)?
And note that CEGE PR is EXTREMELY suspect. On a 1=Trustworthiness of Abraham Lincoln, 10=CTIC (Dendreon being about a 6 or 7 - typical biotech) then CEGE is about a 9. See the following PR (since pulled if I remember correctly).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.